No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.

[1]  James R. Rogers,et al.  Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study , 2017, Arthritis & rheumatology.

[2]  M. Boers,et al.  Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis , 2016, Rheumatology.

[3]  A. Duhamel,et al.  Comparative efficacy of tocilizumab, abatacept and rituximab after non‐TNF inhibitor failure: results from a multicentre study , 2016, International journal of rheumatic diseases.

[4]  N. Wong,et al.  A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event. , 2016, The American journal of cardiology.

[5]  J. Singh,et al.  Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis , 2016, Annals of the rheumatic diseases.

[6]  I. McInnes,et al.  Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis , 2015, Annals of the rheumatic diseases.

[7]  D. Solomon,et al.  Active-comparator design and new-user design in observational studies , 2015, Nature Reviews Rheumatology.

[8]  R. Hansen,et al.  Tumor Necrosis Factor-α Inhibitor Treatment and the Risk of Incident Cardiovascular Events in Patients with Early Rheumatoid Arthritis: A Nested Case-control Study , 2014, The Journal of Rheumatology.

[9]  B. Kissela,et al.  Validity of Claims-Based Stroke Algorithms in Contemporary Medicare Data: Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Linked With Medicare Claims , 2014, Circulation. Cardiovascular quality and outcomes.

[10]  Jeremy A Rassen,et al.  Metrics for covariate balance in cohort studies of causal effects , 2014, Statistics in medicine.

[11]  P. Emery,et al.  Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy , 2014, Annals of the rheumatic diseases.

[12]  R. Leonhart,et al.  Researcher allegiance in psychotherapy outcome research: an overview of reviews. , 2013, Clinical psychology review.

[13]  Abhi Shelat,et al.  One‐to‐many propensity score matching in cohort studies , 2012, Pharmacoepidemiology and drug safety.

[14]  F. Cunningham,et al.  US Government Claims Databases , 2012 .

[15]  J. Gurwitz,et al.  A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data , 2012, Pharmacoepidemiology and drug safety.

[16]  Sebastian Schneeweiss,et al.  A combined comorbidity score predicted mortality in elderly patients better than existing scores. , 2011, Journal of clinical epidemiology.

[17]  H. Leffers,et al.  Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry , 2011, Annals of the rheumatic diseases.

[18]  Jeffrey N Katz,et al.  Validation of rheumatoid arthritis diagnoses in health care utilization data , 2011, Arthritis research & therapy.

[19]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[20]  M. Genovese,et al.  Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study , 2009, Annals of the rheumatic diseases.

[21]  Mohsen Sadatsafavi,et al.  Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. , 2008, Arthritis and rheumatism.

[22]  Jeffrey N Katz,et al.  Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study , 2008, Arthritis research & therapy.

[23]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[24]  Ken Kleinman,et al.  The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[25]  Sebastian Schneeweiss,et al.  Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. , 2004, American heart journal.

[26]  N. Miyasaka,et al.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. , 2004, Arthritis and rheumatism.

[27]  W. Ray,et al.  Evaluating medication effects outside of clinical trials: new-user designs. , 2003, American journal of epidemiology.

[28]  JoAnn E. Manson,et al.  Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis , 2003, Circulation.

[29]  Peter Cummings,et al.  Matched-pair cohort methods in traffic crash research. , 2003, Accident; analysis and prevention.

[30]  Martha J. Radford,et al.  Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .

[31]  Donald Rubin,et al.  Estimating Causal Effects from Large Data Sets Using Propensity Scores , 1997, Annals of Internal Medicine.

[32]  K. Rothman,et al.  VASECTOMY AND NON-FATAL MYOCARDIAL INFARCTION , 1981, The Lancet.